Therefore, to prolong the survival time of advanced NSCLC patients with EGFR mutations, conventional cytotoxic chemotherapy is necessary regardless of whether it is administered before or after treatment with EGFR-TKIs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.